\n
\n
\n
\n
\n
\n GammaTile COE (PRNewsfoto\/GT Medical Technologies)
\n
<\/p>\n
The following physicians are now recognized with achievement:<\/p>\n
Dr.\u00a0Linton Evans, Neurosurgery
\n Dr. Nathan Simmons,\u00a0Neurosurgery
\n Dr. Greg\u00a0Russo, Radiation Oncology
\n Dr.\u00a0Nupur Lala, Neuro-Oncology
\n Dr.\u00a0Tulika Ranjan, Neuro-Oncology <\/p>\n
GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment’s effectiveness against remaining cancer cells and reduce the risk of regrowth.1 \u00a0<\/p>\n
About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care.<\/p>\n
About GammaTile
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within\u2014placed into the surgical cavity at the time of tumor removal\u2014GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.<\/p>\n
Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com and follow @GammaTile on\u00a0Facebook<\/a>,\u00a0Instagram<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0X<\/a>.\u00a0<\/p>\n Media Contact References<\/p>\n Garcia MA\u00a0et al. J Neurooncol. 166:203-212 (2024). <\/p>\n SOURCE GT Medical Technologies<\/p>\n
Dawn Fallon
New Dawn Communications LLC
[email\u00a0protected]<\/a>
732-771-7808<\/p>\n![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA49213&Transmission_Id=202512170800PR_NEWS_USPR_____LA49213&DateId=20251217\")
<\/p>\n